AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0097
Drug name and formulations:		Doxylamine/pyridoxine (Xonvea®)
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	ADRs occur as class effect of antihistamines, licensed product therefore published safety data available
Clinical effectiveness	*Established licensed product*	Superior to placebo
Strength of evidence		Limited/weak
Patient factors	*Published patient factors*	N/A
Cost effectiveness or resource impact	*£*	Higher unit cost compared to current practice.
Place of therapy relative to available treatments	*1/2nd tier*	Not established due to lack of evidence
National guidance and priorities	*NICE, MTRAC*	Not recommended by SMC and AWMSG
Local health priorities	*CCG views*	Not yet reviewed by neighbouring CCGs so no evidence of "post code prescribing"
Equity of access	*Equality assessment*	
Stakeholder views	*Define wider groups to be engaged*	RCOG
Implementation requirements	*Requires, RICAD ESCA etc.*	

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	Not approved. Rationale: Lack of evidence of clinical efficacy compared to currently recommended treatments. Unclear of number of patients expected to treat. Uncertain if costs will be offset by reduction in admissions.
Formulary status (RAG) and rationale	
Implementation requirements:	
Implementation monitoring:	

Copyright © Midlands & Lancashire CSU